Shares of Ujjivan Small Finance Bank will be in focus on listing. The issue opened for bidding on Monday, 2 December 2019 and closed on Wednesday, 4 December 2019. The price band was fixed at Rs 36 to Rs 37 per share. The initial public offer (IPO) of Ujjivan Small Finance Bank received bids for 2053.80 crore shares as against 12.39 crore shares on offer, as per the National Stock Exchange of India (NSE) website data. The issue was subscribed 165.68 times. The qualified institutional buyers (QIBs) category was subscribed 110.72 times while the non-institutional investors category was subscribed 473 times. The retail individual investors (RIIs) category was subscribed 49.09 times.
Shares of Maruti Suzuki India will be in focus on partnering with Federal Bank for dealer and auto financing. Maruti Suzuki India said it has joined hands with Federal Bank to provide dealer finance and customised auto retail financing solutions to customers. In August 2019, Maruti Suzuki India had inducted Federal Bank as an approved partner for dealer inventory funding. The latest tie-up for retail financing to customers will further offer comprehensive loan access facilities to Maruti Suzuki India dealers as well as customers
Ultratech Cement said the company has approved the allotment of 2,500 listed, Unsecured Non-Convertible Debentures of Rs 10,00,000 each aggregating to Rs 250 crore on private placement basis. The NCDs with 3 year tenure will carry interest of 6.72% and will be listed on the NSE.
IDFC First Bank said India Ratings & Research Private Limited has assigned 'IND AA+/ Negative' Rating/ Outlook in respect of Bank's 'Basel III - Tier 2 Bonds' of Rs 2000 crore (Size of Issue) and have affirmed existing ratings (IND AA+/ Negative) in respect of Bank's other senior debt instruments (Infra Bonds & NCDs).
Cipla said Avenue Therapeutics Inc., USA, a company focused on the development of intravenous tramadol for the US submitted a New Drug Application (NDA) to the US FDA for IV tramadol for the management of moderate to moderately severe pain in adults in a medically supervised health care setting. Avenue Therapeutics, Inc. Is an associate company of Cipla.
Cadila Healthcare said it has launched affordable oral anti-diabetic tablet Vinglyn. The drug belongs to the class of oral anti-diabetic agents, known as DPP4 inhibitors, which have shown promise in achieving glycaemic control without deterioration in beta cell function and are one of the recent advancements in diabetes care and management. Vinglyn and Vinglyn M will be marketed by Zydus Healthcare Ltd.
Vodafone Idea denied reports about negotiations are taking place with Brookfields or Edelweiss to sell some assets. The fact that the company intends to monetize its optic fibre business and data centre was disclosed in the quarterly report sent to the Stock Exchanges on 14 November 2019.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
